Hailing the government's move, Surajit Pal, pharma analyst at Prabhudas Lilladher, says the aim of regulation is to prevent rampant use of antibiotics. He says Abbott is likely to be severely impacted by the move as it has around 15.4 percent exposure to fixed-dosed combinations.

Indore facility to start production in 2 months: Ipca Labs

AK Jain, ED, Ipca Labs says the company's pain management segment is doing ver well and it has leadership in rheumatoid arthritis with substantial market share. The company's Indore facility will start production in 2 months.

Eyeing 18-20% growth in domestic market in FY13: Ipca Labs

Exectuive director of Ipca Labs AK Jain told CNBC-TV18 that Ipca Lanbs aims to grow by 18-20% in the domestic market in FY13.

Ipca Labs hopes to achieve 18-20% growth for FY12

AK Jain, the executive director of Ipca Labs, in an interview on CNBC-TV18, talks about the latest happenings in the company and sector.

Expect USFDA nod for Indore unit in three months: Ipca Labs

In an interview with CNBC-TV18, AK Jain, ED of Ipca Labs said, "We are waiting for the US FDA to inspect our SEZ Indore plant. This product will be produced there so, till the time we get the approval for the plant we will not be able to take the commercial production of this product."